Navidea's Macrophage heralds preclinical drug conjugate for Kaposi's sarcoma; Biogen links up with AGTC on blindness gene therapy;

> Macrophage Therapeutics, part of Navidea ($NAVB), announced preclinical results from its study of doxorubicin linked to its drug conjugate Manocept as a treatment for Kaposi's sarcoma. Release

> Biogen ($BIIB) and AGTC have joined forces to develop gene therapies for ophthalmologic use. AGTC's main foci are diseases of the retina that can lead to blindness. Release

Suggested Articles

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.

Genentech's Port Delivery System with ranibizumab matched Lucentis eye injections in a late-stage, wet age-related macular degeneration trial.

Honeywell aims to wean the industry of its glass habit with Aclar Edge, a new line of bottles and vials made with the company's patented plastic.